Shots:
- The US FDA has granted 510(k) to both TalisMann & StimTrial for the management of chronic pain; limited US launch is planned in Q3’25, with broader rollout expected in early 2026
- TalisMann integrates patented electric field conduction with a pulse generator to target deeper, larger nerves, & deliver long-term relief from chronic nerve pain, as well as expand response to neuromodulation therapy
- StimTrial is a trial lead that allows physicians to assess patient response to PNS therapy, which supports broader physician adoption & payer reimbursement in settings requiring trial-based evaluations
Ref: Globenewswire | Image: Bioventus | Press Release
Related News:- Minnesota Medical Technologies Receives the US FDA’s 510(k) Clearance for StaySure to Manage Fecal Incontinence
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
